Drug Trial Radar · NCT06746311
This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Nov 22, 2022
Primary completion
May 13, 2024
Study completion Jun 17, 2024
Sponsor
- Lead sponsor
- Suzhou HepaThera Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1 Study of HT-101 in Healthy Subjects and Patients With Chronic Hepatitis B The trial consisted of two components. Part A involved a single ascending dose study where healthy participants were administered one dose of HT-101 or placebo subcutaneously (SC). Part B involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered two dose of HT-101 or placebo every 4 weeks subcutaneously (SC).
Conditions
- Chronic Hepatitis b
Interventions
HT-101Drug
Single dose of HT-101 administered subcutaneously.
HT-101Drug
Multiple dose of HT-101 administered subcutaneously.
PlaceboDrug
Placebo, containing no active ingredient, administered subcutaneouly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From enrollment to the end of treatment at 24 weeks
- Clinically significant abnormalitiesTime frame: From enrollment to the end of treatment at 24 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Beijing Friendship Hospital
Beijing, Beijing Municipality, China
Nanfang Hospital
Guangzhou, Guangdong, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
Yanbian University Hospital
Yanji, Jilin, China
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.